Eisai, a major pharmaceutical company, has announced that the results of final-stage clinical trials of a new treatment for Alzheimer's disease have confirmed that it is effective in suppressing the worsening of symptoms.
The company plans to apply for approval in Japan, Europe and the United States by the end of March next year.
On the 28th, "Eisai" announced the results of the final stage clinical trial of "lecanemab", a new treatment for Alzheimer's disease, which is being jointly developed with the American pharmaceutical company "Biogen".
According to it, the clinical trial will be conducted from March 2019 in the United States, Japan, Europe, etc., with a total of about 1,800 patients with mild dementia and patients in the pre-onset stage, and will be administered once every two weeks. We divided the patients into a group that administers the medicine at a pace and a group that administers a placebo, and examined changes in the cognitive function of the patients in the form of evaluation by doctors.
As a result, one and a half years after administration, in the group that received lecanemab, the worsening of symptoms was suppressed by 27%, confirming efficacy.
"Lecanemab" aims to suppress the progression of the disease itself by binding antibodies to the abnormal protein "amyloid β" that accumulates in the brains of Alzheimer's disease patients and removing it by preventing nerve cell damage.
The company will report detailed analysis results at a dementia conference to be held in the United States in November, and will apply for approval in the United States, Japan, and the EU by the end of March next year.